- Home
- AVTX vs CBAT Comparison
AVTX vs CBAT Comparison
Compare AVTX & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- CBAT
- Stock Information
- Founded
- AVTX 2011
- CBAT 1999
- Country
- AVTX United States
- CBAT China
- Employees
- AVTX N/A
- CBAT N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- CBAT Industrial Machinery/Components
- Sector
- AVTX Health Care
- CBAT Miscellaneous
- Exchange
- AVTX Nasdaq
- CBAT Nasdaq
- Market Cap
- AVTX 88.4M
- CBAT 71.6M
- IPO Year
- AVTX 2015
- CBAT N/A
- Fundamental
- Price
- AVTX $4.41
- CBAT $0.70
- Analyst Decision
- AVTX Strong Buy
- CBAT
- Analyst Count
- AVTX 7
- CBAT 0
- Target Price
- AVTX $34.33
- CBAT N/A
- AVG Volume (30 Days)
- AVTX 69.6K
- CBAT 192.3K
- Earning Date
- AVTX 05-12-2025
- CBAT 05-09-2025
- Dividend Yield
- AVTX N/A
- CBAT N/A
- EPS Growth
- AVTX N/A
- CBAT N/A
- EPS
- AVTX N/A
- CBAT 0.13
- Revenue
- AVTX $441,000.00
- CBAT $176,614,609.00
- Revenue This Year
- AVTX N/A
- CBAT $28.79
- Revenue Next Year
- AVTX N/A
- CBAT $36.77
- P/E Ratio
- AVTX N/A
- CBAT $5.42
- Revenue Growth
- AVTX N/A
- CBAT N/A
- 52 Week Low
- AVTX $4.44
- CBAT $0.57
- 52 Week High
- AVTX $17.49
- CBAT $2.08
- Technical
- Relative Strength Index (RSI)
- AVTX 29.58
- CBAT 41.50
- Support Level
- AVTX $4.59
- CBAT $0.63
- Resistance Level
- AVTX $5.85
- CBAT $0.73
- Average True Range (ATR)
- AVTX 0.85
- CBAT 0.06
- MACD
- AVTX -0.21
- CBAT -0.00
- Stochastic Oscillator
- AVTX 2.41
- CBAT 56.52
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.